Stoke Therapeutics jumps on positive early-stage data for epilepsy drug

Stoke Therapeutics

26/03/2024 09:54

** Drug developer Stoke Therapeutics' shares  STOK.O  climb
69.7% to $11.03 premarket 
    ** Co late on Monday announced positive early-stage data for
its experimental drug to treat a type of epilepsy in patients
aged 2 to 18 who were already taking anti-seizure medicines
        ** STOK says the drug helped substantially reduce
seizures and also improved cognition and behavior
  
    ** Co says the drug has been has been generally
well-tolerated
    ** STOK plans to meet with regulatory agencies to discuss
plans for a registrational study and provide updates on the
discussions later in 2024
    ** Up to last close, stock has risen 23,6% YTD 

 (Reporting by Sneha S K in Bengaluru)
 ((Sneha.SK@thomsonreuters.com;))